Cantor Fitzgerald initiated coverage on Generate Biomedicines
$GENB
Biotechnology: Pharmaceutical Preparations
Health Care
Cantor Fitzgerald initiated coverage of Generate Biomedicines with a rating of Overweight
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/13/2026 | $16.00 | Buy | H.C. Wainwright |
| 3/24/2026 | $24.00 | Overweight | Piper Sandler |
| 3/24/2026 | $20.00 | Overweight | Morgan Stanley |
| 3/24/2026 | Overweight | Cantor Fitzgerald | |
| 3/24/2026 | $30.00 | Buy | Guggenheim |
| 3/24/2026 | $26.00 | Buy | Goldman |
3 - Generate Biomedicines, Inc. (0002100782) (Issuer)
4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
8-K - Generate Biomedicines, Inc. (0002100782) (Filer)
H.C. Wainwright initiated coverage of Generate Biomedicines with a rating of Buy and set a new price target of $16.00
Piper Sandler initiated coverage of Generate Biomedicines with a rating of Overweight and set a new price target of $24.00
Morgan Stanley initiated coverage of Generate Biomedicines with a rating of Overweight and set a new price target of $20.00
4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
4 - Generate Biomedicines, Inc. (0002100782) (Issuer)